David Shapiro Sells 3,425 Shares of Intercept Pharmaceuticals Inc (ICPT) Stock

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 3,425 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $102.95, for a total transaction of $352,603.75. Following the sale, the insider now directly owns 42,577 shares in the company, valued at approximately $4,383,302.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Shapiro also recently made the following trade(s):

  • On Thursday, November 1st, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $96.32, for a total transaction of $192,640.00.
  • On Friday, October 5th, David Shapiro sold 759 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $110.65, for a total transaction of $83,983.35.
  • On Wednesday, September 5th, David Shapiro sold 4,917 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $111.43, for a total transaction of $547,901.31.

ICPT traded down $4.98 on Friday, hitting $108.81. The company’s stock had a trading volume of 315,653 shares, compared to its average volume of 519,602. The company has a market cap of $3.39 billion, a PE ratio of -7.57 and a beta of -1.08. Intercept Pharmaceuticals Inc has a 12 month low of $51.05 and a 12 month high of $133.74. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The company had revenue of $47.00 million during the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. Intercept Pharmaceuticals’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the firm earned ($2.89) EPS. Research analysts forecast that Intercept Pharmaceuticals Inc will post -10 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on ICPT shares. ValuEngine lowered shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Laidlaw lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating and upped their target price for the stock from $90.00 to $95.00 in a report on Friday, August 3rd. Roth Capital began coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, September 12th. They issued a “buy” rating and a $192.00 target price on the stock. Finally, Cantor Fitzgerald set a $69.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 2nd. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $140.06.

A number of hedge funds and other institutional investors have recently bought and sold shares of ICPT. Strs Ohio purchased a new stake in Intercept Pharmaceuticals in the 3rd quarter worth approximately $126,000. Chicago Equity Partners LLC purchased a new stake in Intercept Pharmaceuticals in the 3rd quarter worth approximately $215,000. GWM Advisors LLC purchased a new stake in Intercept Pharmaceuticals in the 3rd quarter worth approximately $220,000. Tocqueville Asset Management L.P. purchased a new stake in Intercept Pharmaceuticals in the 2nd quarter worth approximately $252,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Intercept Pharmaceuticals in the 2nd quarter worth approximately $264,000. Institutional investors and hedge funds own 70.07% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.baseballdailydigest.com/2018/11/10/intercept-pharmaceuticals-inc-icpt-insider-sells-352603-75-in-stock.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Story: Balance Sheet

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply